Platform Specialty Products Corp
Form 424B2
September 16, 2016

Filed Pursuant to Rule 424(b)(2)
Registration No. 333-212480

PROSPECTUS SUPPLEMENT
(To Prospectus dated July 12, 2016)

$350,000,000
COMMON STOCK

We are offering up to 42,424,242 shares of our common stock (the "Shares").

Our shares of common stock are listed on the New York Stock Exchange (the "NYSE") under the ticker symbol "PAH." The closing sale price on the NYSE for our shares of common stock on September 15, 2016 was $8.35 per share.

Investing in our common stock involves risks. Please refer to the "Risk Factors" section beginning on page S-24 of this prospectus supplement and page 4 of the accompanying prospectus.

	Per share	Total
Price to the public	$ 8.25	$350,000,000
Underwriting discounts and commissions	0.226875	9,625,000
Proceeds to Platform (before expenses)	8.023125	340,375,000

See "Underwriting" on page S-36 for additional information regarding underwriting compensation.

The underwriters may also exercise their option to purchase up to an additional 6,363,636 shares from us, at the public offering price, less the underwriting discount, within 30 days after the date of this prospectus supplement.

Neither the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the prospectus to which it relates. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the Shares against payment on or about September 21, 2016.

Joint Book-Running Managers

Credit Suisse Goldman, Sachs & Co. UBS Investment Bank

Co-Managers

Nomura Deutsche Bank Securities HSBC

Citizens Capital Markets, Inc. Credit Agricole CIB Morgan Stanley

BTIG CJS Securities

Prospectus Supplement dated September 15, 2016

TABLE OF CONTENTS

Prospectus Supplement

Prospectus

You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus prepared by us or on our behalf. We and the underwriters have not authorized anyone to provide you with different or additional information. If you receive different or additional information, you should not rely on it. We and the underwriters are offering to sell, and seeking offers to buy, Shares only in jurisdictions where offers and sales are permitted. The information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus is accurate only as of its respective date, regardless of the time of delivery of the applicable document or of any sale of Shares. Our business, financial condition, results of operations and prospects may have changed since those dates.

ABOUT THIS PROSPECTUS SUPPLEMENT

This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of the common stock we are offering and certain other matters relating to us and our financial condition. The second part, the accompanying prospectus, provides more general information about securities we may offer from time to time, including securities other than the common stock being offered by this prospectus supplement. You should read this prospectus supplement along with the accompanying prospectus, as well as the documents incorporated by reference herein and therein. This prospectus supplement and the accompanying prospectus are part of a shelf registration statement that we filed with the SEC under the Securities Act of 1933, as amended (the "Securities Act"). If the description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement.

It is important for you to read and consider all of the information contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein in making your investment decision. You should also read and consider the information in the documents we have referred you to in "Where You Can Find More Information" on page S-43 of this prospectus supplement and page 18 of the accompanying prospectus.

We include cross-references in this prospectus supplement and the accompanying prospectus to captions in these materials where you can find additional related discussions. The table of contents in this prospectus supplement provides the pages on which those captions are located.

As used in this prospectus supplement, unless the context otherwise requires, all references to "we," "us," "our," the "Company" and "Platform" refer to Platform Specialty Products Corporation, a Delaware corporation, and its subsidiaries, collectively, for all periods subsequent to April 23, 2013 (inception).

All references in this prospectus supplement to our "Predecessor" refer to MacDermid, Incorporated, a Connecticut corporation ("MacDermid") and its subsidiaries for all periods prior to our acquisition of MacDermid on October 31, 2013 (the "MacDermid Acquisition"). As used in this prospectus, the "Successor 2016 Six Month Period" refers to the period from January 1, 2016 to June 30, 2016, the "Successor 2015 Six Month Period" refers to the period from January 1, 2015 to June 30, 2015, the "Successor 2015 Period" refers to the fiscal year ended December 31, 2015, the "Successor 2014 Period" refers to the fiscal year ended December 31, 2014, the "Successor 2013 Period" refers to the period from April 23, 2013 (inception) through December 31, 2013 and the "Predecessor 2013 Period" refers to the ten month period from January 1, 2013 through October 31, 2013.

All references in this prospectus supplement to:

- our "2015 Annual Report" refer to our annual report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC on March 11, 2016;
- our "2016 Q1 Form 10-Q" refer to our quarterly report on Form 10-Q for the three months ended March 31, 2016 filed with the SEC on May 10, 2016;
- our "2016 Q2 Form 10-Q" refer to our quarterly report on Form 10-Q for the three and six months ended June 30, 2016 filed with the SEC on August 9, 2016;
- the "Agriphar Acquisition" refer to our acquisition of Percival S.A., including Percival S.A.'s agrochemical business, Agriphar (collectively, "Agriphar"), on October 1, 2014;
- the "CAS Acquisition" refer to our acquisition of the Chemtura AgroSolutions business ("CAS") of Chemtura Corporation ("Chemtura") on November 3, 2014;
- the "Arysta Acquisition" refer to our acquisition of Arysta LifeScience Limited ("Arysta" or "Arysta LifeScience") on February 13, 2015;
- the "OMG Acquisition" refer to our acquisition of the Electronic Chemicals and Photomasks businesses of OM Group, Inc. (collectively, the "OMG Businesses") on October 28, 2015;
- the "Alent Acquisition" refer to our acquisition of Alent plc ("Alent") on December 1, 2015;
- the "OMG Malaysia Acquisition" refer to our acquisition of OMG Electronic Chemicals (M) Sdn Bhd, a subsidiary of OM Group, Inc. located in Malaysia ("OMG Malaysia"), on January 31, 2016;
- the "Agricultural Solutions Acquisitions" refer to the Agriphar Acquisition, the Arysta Acquisition and the CAS Acquisition, collectively;

- the "Performance Solutions Acquisitions" refer to the Alent Acquisition and the OMG Acquisition and the OMG Malaysia Acquisition, collectively;
- the "Prior Acquisitions" refer to the Agriphar Acquisition, the CAS Acquisition, the Arysta Acquisition, the OMG Acquisition, the Alent Acquisition and the OMG Malaysia Acquisition, collectively; and
- our “common stock” refer to the common stock of Platform, par value $0.01 per share.

NON-GAAP FINANCIAL MEASURES

Non-GAAP Financial Measures

The SEC has adopted rules to regulate the use of "non-GAAP financial measures" that are derived on the basis of methodologies other than in accordance with U.S. generally accepted accounting principles ("GAAP"). This prospectus supplement contains comparable net (loss) income available to common stockholders, comparable sales, comparable cost of sales, comparable gross profit, Adjusted EBITDA, segment comparable Adjusted EBITDA, and segment comparable sales, which are non-GAAP financial measures. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein also present additional non-GAAP financial measures, including adjusted net sales change, adjusted cost of sales change, adjusted gross profit change, adjusted selling, technical, general and administrative expense change, adjusted research and development expense change and adjusted operating profit change, in each case adjusted for acquisitions and changes in foreign currency translations, which are also non-GAAP financial measures.

For purposes of Regulation G and Section 10(e) of Regulation S-K, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statements of operations, balance sheets, or statements of cash flows of the company; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. Pursuant to the requirements of Regulation G and Item 10(e) of Regulation S-K, Platform has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

These non-GAAP financial measures are provided because management uses this non-GAAP financial information as an indicator of business performance, and evaluates overall management with respect to such indicators. Management believes these non-GAAP financial measures provide useful information about our operating performance by excluding certain items that we believe are not representative of our business performance and including other items that we believe are useful in evaluating our business. We also believe that these non-GAAP financial measures provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures. We use these non-GAAP financial measures as key metrics in the evaluation of the Company's performance and our consolidated financial results and, in part, in the determination of cash bonuses for the Company's executive officers. However, these non-GAAP financial measures should be considered in addition to, not a substitute for, measures of financial performance prepared in accordance with GAAP.

For definitions of our non-GAAP financial measures and additional information on why we present them, the limitations associated with their use and their reconciliations to the most comparable applicable GAAP financial measures, see "Summary Financial Data."

Financial Statements of Alent and Arysta

Alent's consolidated financial statements for the years ended December 31, 2014 and 2013 and for the nine months ended September 30, 2015 and Arysta's consolidated financial statements for the years ended December 31, 2014 and 2013, all incorporated by reference in this prospectus supplement and the accompanying prospectus, were prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

TRADEMARKS AND TRADE NAMES

This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein contain or incorporate by reference some of our trademarks and trade names. All other trademarks or trade names of any other company appearing or incorporated by reference in this prospectus supplement, the accompanying prospectus or the documents incorporated by reference herein and therein belong to their respective owners. Solely for convenience, the trademarks and trade names in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies' trade names to imply a relationship with, or endorsement or sponsorship of us by, these other companies.

MARKET AND INDUSTRY DATA

We obtained the industry, market and competitive position data described or incorporated by reference in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. While we believe our internal estimates and research are reliable and the market definitions are appropriate, such estimates, research and definitions have not been verified by any independent source. We caution you not to place undue reliance on this data.

UNAUDITED PRO FORMA FINANCIAL INFORMATION

The Alent Acquisition, which was consummated on December 1, 2015, was a significant acquisition to us (at a significance level of greater than fifty percent) under Rule 3-05 and 1-02(w) of Regulation S-X under the Securities Act. The Arysta Acquisition, which was consummated on February 13, 2015, was also a significant acquisition to us (at a significance level of greater than seventy percent) under Rule 3-05 and 1-02(w) of Regulation S-X under the Securities Act. As a result, we have incorporated by reference in this prospectus supplement and the accompanying prospectus the historical financial statements of Alent and Arysta and unaudited pro forma financial information based on the historical financial statements of Platform, Alent and Arysta, combined and adjusted to give effect to the Alent Acquisition and the Arysta Acquisition and their respective financings as if each had occurred as of January 1, 2015 for purposes of the statements of operations. The unaudited pro forma statements of operations do not reflect the OMG Acquisition or the OMG Malaysia Acquisition, consummated on October 28, 2015 and January 31, 2016, respectively, because neither the OMG Acquisition nor the OMG Malaysia Acquisition, individually or in the aggregate, was significant as defined by Rule 1-02(w) of Regulation S-X. The Agriphar Acquisition and the CAS Acquisition were completed on October 1, 2014 and November 3, 2014, respectively, and therefore are already reflected in Platform's financial statements for all of fiscal year 2015.

The unaudited pro forma combined consolidated financial information incorporated by reference in this prospectus supplement and the accompanying prospectus is for informational purposes only and is not intended to represent or to be indicative of the consolidated results of operations or financial position that we would have reported had the Alent Acquisition and the Arysta Acquisition been completed as of the dates set forth in the unaudited pro forma combined consolidated financial information, and should not be taken as indicative of our future consolidated results of operations or financial position. The unaudited pro forma financial data has been prepared in accordance with the requirements of Article 11 of Regulation S-X of the Securities Act. However, neither the assumptions underlying the pro forma adjustments nor the resulting pro forma financial information have been audited or reviewed in accordance with any generally accepted auditing standards.

The unaudited pro forma combined consolidated financial information should be read in conjunction with the historical financial statements of Platform, Alent and Arysta, all incorporated by reference in this prospectus supplement and the accompanying prospectus.

PROSPECTUS SUPPLEMENT SUMMARY

This summary highlights information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does not contain all of the information that you should consider before making an investment decision. We urge you to read this entire prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or therein carefully, including the financial statements of Platform, Alent and Arysta and the notes to those financial statements incorporated by reference herein. Please also read "Risk Factors" contained herein, in the accompanying prospectus and in the documents incorporated by reference herein and therein for more information about important risks that you should consider before investing in our common stock. This prospectus contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors. See “Forward-Looking Statements” for more information relating to these factors.

Our Company

We are a global, diversified producer of high-technology specialty chemical products. Our business involves the formulation of a broad range of solutions-oriented specialty chemicals, which are sold into multiple industries, including agricultural, animal health, electronics, graphic arts, plating, and offshore oil and gas production and drilling. We refer to our products as "dynamic chemistries" due to their intricate chemical compositions. Our dynamic chemistries are used in a wide variety of attractive niche markets and we believe that the majority of our operations hold strong positions in the product markets they serve.

Our strategy is to acquire and maintain leading positions in niche sectors of high-growth markets. As our name "Platform Specialty Products Corporation" implies, we continually seek opportunities to acquire and consolidate specialty chemical businesses on a global basis, particularly those meeting our "Asset-Lite, High-Touch" philosophy, which involves prioritizing extensive resources to research and development and highly technical customer service, while managing conservatively our investments in fixed assets and capital expenditures. We regularly review acquisition opportunities and may acquire businesses that meet our acquisition criteria when we deem it to be financially prudent. To date, we have completed seven acquisitions: the MacDermid Acquisition on October 31, 2013, the Agriphar Acquisition on October 1, 2014, the CAS Acquisition on November 3, 2014, the Arysta Acquisition on February 13, 2015, the OMG Acquisition on October 28, 2015, the Alent Acquisition on December 1, 2015 and the OMG Malaysia Acquisition on January 31, 2016.

We generate revenue through the formulation and sale of our dynamic chemistries and by providing highly-technical services to our customers through our extensive global network of specially trained service personnel. Our personnel work closely with our customers to ensure that the intricate chemical composition and function of our products are maintained as intended while ensuring that these products are applied safely and effectively by users globally. We believe that the fragmented nature of the specialty chemical products market will continue to provide significant opportunities for growth and that our combined company will provide a strong platform on which to grow our business and expand our market shares in key geographic markets, particularly in emerging markets. For Performance Solutions, we believe the current addressable market is approximately $8 billion while its global addressable market is approximately $15 billion. For Agricultural Solutions, we believe the global addressable market is $54 billion.

We expect that the Prior Acquisitions and any future acquisitions will enhance our growth by extending our products breadth, developing higher-margin products and growing internationally. We intend to extend many of our product offerings through the development of new applications for our existing products or through synergistic combinations. Our goal is to target those geographies with attractive market fundamentals where our strengths in marketing, portfolio development, registration and customer education can add value for our customers.

Our History

We were initially incorporated with limited liability under the laws of the British Virgin Islands on April 23, 2013 under the name Platform Acquisition Holdings Limited. We completed our initial public offering in the United Kingdom on May 22, 2013, raising net proceeds of approximately $881 million, and were listed on the London Stock Exchange.

On October 31, 2013, we indirectly acquired substantially all of the equity of MacDermid Holdings, LLC ("MacDermid Holdings"), which, at the time, owned approximately 97% of MacDermid. As a result, we became a holding company for the MacDermid business. We acquired the remaining 3% of MacDermid on March 4, 2014. Concurrently with the closing of the MacDermid Acquisition, we changed our name to Platform Specialty Products Corporation. On January 22, 2014, we changed our jurisdiction of incorporation from the British Virgin Islands to Delaware, and on January 23, 2014, our shares of common stock began trading on the NYSE under the ticker symbol "PAH."

Our Business

We currently operate our business in two reportable business segments, Performance Solutions and Agricultural Solutions, as described below:

Performance Solutions – Our Performance Solutions segment formulates and markets dynamic chemistry solutions that are used in automotive production, commercial packaging and printing, electronics, and oil and gas production and drilling. Our products include surface and coating materials, functional convention coatings, electronic assembly materials, water-based hydraulic control fluids and photopolymers. In conjunction with the sale of these products, we provide extensive technical service and support when necessary to ensure superior performance of their application. Within this segment, we provide specialty chemicals to the following industries: Electronics, Electronics Assembly Materials, Industrial, Offshore and Commercial Packing and Printing. For the Electronics industry, we design and formulate a complete line of proprietary “wet” dynamic chemistries that our customers use to process the surface of printed circuit boards and other electronic components they manufacture. For the Electronics Assembly Materials industry, we develop, manufacture and sell innovative interconnected materials, primarily in the electronics market, used to assemble printed circuit boards and advanced semiconductor packaging. We also offer a small water treatment product line. For the Industrial industry, our dynamic chemistries are used for finishing, cleaning and providing surface coatings for a broad range of metal and non-metal surfaces which improve the performance or look of a component of an industrial part or process. For the Offshore industry, we produce water-based hydraulic control fluids for major oil and gas companies and drilling contractors for offshore deep water production and drilling applications. For the Commercial Packaging and Printing industries, we produce photopolymers through an extensive line of flexographic plates, used to produce printing plates for transferring images onto commercial packaging, including packaging for consumer food products, pet food bags, corrugated boxes, labels and beverage containers. In addition, we also produce photopolymer printing plates for the flexographic and letterpress newspaper and publications markets. Our Performance Solutions segment employs approximately 4,500 personnel which operate mainly in the Americas, Asia/Pacific region and Europe.

Agricultural Solutions – Our Agricultural Solutions segment is based on a solutions-oriented business model that focuses on product innovation to address an ever-increasing need for higher crop yield and quality. We offer to growers diverse crop protection solutions from weeds (herbicides), insects (insecticides) and diseases (fungicides), in foliar and seed treatment applications. We also offer a wide variety of proven biosolutions, including biostimulants, which stimulate plant growth and reproductive development, innovative nutrition, which optimizes the nutrition of plants, and biocontrol products, such as bioinsecticides and biofungicides, which perform the same task as conventional crop protection products without chemical residues. We emphasize farmer economics and food safety by combining, when possible, biosolutions with crop protection and seed treatment agrochemicals. Our Global Value Added Portfolio ("GVAP") consists of agrochemicals in the herbicides, insecticides, fungicides and seed treatment categories, based on patented or proprietary off-patent AIs. Our Global BioSolutions Portfolio ("GBP") includes biostimulants, innovative nutrition and biocontrol products. We consider our GVAP and GBP to be key pillars for our sustainable growth. In addition, we offer regional off-patent AIs and certain non-crop products, including animal health products, such as honey bee protective miticides and certain veterinary vaccines. We employ approximately 4,000 personnel with a significant presence on high-growth regions such as Africa and the Middle East, South Asia, Latin America and Central and Eastern Europe.

Our operating segments include significant foreign operations. There are certain risks associated with our foreign operations. See Risk Factors— "Our substantial international operations subject us to risks not faced by domestic competitors" and "We are exposed to fluctuations in currency exchange rates, which may adversely affect our operating results and may significantly affect the comparability of our results between financial periods" included in this prospectus supplement.

Recent Developments

On July 12, 2016, we filed with the SEC a shelf registration statement on Form S-3, to which this prospectus supplement and the accompanying prospectus form a part and under which we may issue up to $1.0 billion of securities, including common stock, preferred stock and debt securities. The shelf registration statement was declared effective by the SEC on July 26, 2016.

On September 9, 2016, we agreed with Nalozo S.à.r.l. (the "Arysta seller") that from October 20, 2016 until the close of business on December 15, 2016, we may (i) settle all of our obligations with respect to our shares of Series B convertible preferred stock (the "Series B Convertible Preferred Stock") in exchange for a cash payment of $1.00 and the issuance of 5,500,000 shares of our common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta seller, and (ii) settle for a payment of $460 million, our obligation to pay a “make whole payment” to the Arysta seller pursuant to a share purchase agreement among us, the Arysta seller and certain other parties thereto, dated as of October 20, 2014, as amended. The agreement includes mutual releases from any and all claims the parties may have had related to the Arysta share purchase agreement.

Rakesh Sachdev joined Platform on January 5, 2016 as our Chief Executive Officer. The board of directors of Platform (the "Board") also appointed Mr. Sachdev to serve as a Director on Platform's Board. Mr. Sachdev joined Platform with more than 28 years of management experience at leading public companies having most recently served as President and Chief Executive Officer of Sigma-Aldrich Corporation since 2010 through its recent acquisition by Merck KGaA. His previous positions at Sigma Aldrich included Vice President and Chief Financial Officer as well as Chief Administrative Officer. Earlier in his career, Mr. Sachdev held numerous senior management positions at ArvinMeritor, Inc. and Cummins Inc.

Diego Lopez Casanello joined Platform on February 1, 2016 as President of our Agricultural Solutions segment. Mr. Casanello joined Platform with over 20 years of experience at global diversified chemicals manufacturer BASF, having most recently served as Senior Vice President and head of the Agricultural Products Division, Asia Pacific. His previous positions at BASF included Senior Vice President of the Performance Chemicals Division, North America, as well as Chief Executive Officer and Managing Director of BASF Argentina. Mr. Casanello has held numerous other roles within the Agricultural Products Division of BASF, including Head of Global Marketing for Seed Treatment, Global Manager of New Business Development and Business Director for South Europe.

John E. Capps joined Platform on May 31, 2016 as Executive Vice President, General Counsel and Secretary. Before joining Platform, Mr. Capps was Executive Vice President - Administration, General Counsel and Secretary of Jarden Corporation, a Fortune 500 broad-based consumer products company ("Jarden"), where he served until April 2016 when Jarden merged with Newell Brands Inc. Previously, Mr. Capps worked with American Household, Inc. which was acquired by Jarden in January 2005, and as a private lawyer with the firm Sullivan & Cromwell LLP.

On January 31, 2016, we completed the OMG Malaysia Acquisition for an aggregate purchase price of approximately $124 million, net of acquired cash and closing working capital adjustments. OMG Malaysia is included in our Performance Solutions business segment. We financed the OMG Malaysia Acquisition with the proceeds from the public offering of shares of our common stock which closed on June 29, 2015.

As previously disclosed in our 2015 Annual Report, 2016 Q1 Form 10-Q and 2016 Q2 Form 10-Q, in connection with the implementation of our internal controls, policies and procedures at Arysta, a newly acquired subsidiary, following our acquisition of that business, we discovered certain payments made to third-party agents in connection with Arysta’s government tender business in West Africa which may be illegal or otherwise inappropriate. We have engaged outside counsel and an outside accounting firm to conduct an internal investigation (the "Internal Investigation") to review the legality of these and other payments made in Arysta’s West Africa tender business, including Arysta’s compliance with the Foreign Corrupt Practices Act of 1977 (the "FCPA"). We contacted the SEC and the U.S. Department of Justice to voluntarily inform them of this matter and we are fully cooperating with these governmental authorities as the Internal Investigation continues and as they review the matter. Although the Internal Investigation is still ongoing, at this time, based on the results to date, management does not currently believe that the amount of the payments in question, or any revenue or operating income related to those payments, are material to our business, results of operations, financial condition or liquidity.

In March and April 2016, a class action lawsuit entitled Dillard v. Platform Specialty Products Corporation, et al. and a shareholder derivative action entitled Tuttelman v. Platform Specialty Products Corporation, et al., respectively, were filed against Platform, certain of its former and current executive officers and, in the case of the derivative action, its directors in the U.S. District Court for the Southern District of Florida alleging that the defendants made material false and misleading statements relating to the Company's business, operational and compliance policies in light of the Internal Investigation. In June 2016, the shareholder derivative action was dismissed by the Court. On June 29, 2016, the Court appointed joint lead plaintiffs in the class action lawsuit, and on July 20, 2016, the plaintiffs filed an amended complaint with an expanded class period but stating substantially similar claims to those contained in the original complaint. The class action lawsuit, which remains pending, is seeking unspecified damages. We believe this proceeding is without merit and intend to defend it vigorously.

As previously described in Note 26, Restatement of Unaudited Condensed Consolidated Financial Statements (unaudited), to the Consolidated Financial Statements included in our 2015 Annual Report, during the preparation of our annual financial statements for the fiscal year ended December 31, 2015, we discovered an error related to our income tax provision for the quarter ended September 30, 2015. The error was the result of recording an unrealized loss associated with foreign currency hedges entered into in connection with the Alent Acquisition as a temporary rather than permanent difference for income tax accounting purposes. As a result, we concluded that we were required to restate our unaudited financial information for our third quarter ended September 30, 2015. Our 2015 Annual Report includes the restatement of our unaudited financial statements for the third quarter ended September 30, 2015 in the aforementioned Note 26. Subsequently, as previously disclosed in our 2016 Q1 Form 10-Q, an error to goodwill and foreign currency translation adjustment of $72.8 million occurred relating to the Arysta Acquisition and was corrected as an out-of-period adjustment in such quarterly report. We subsequently concluded that this previously disclosed error also had the effect of understating cash flows provided by operating activities and cash flows used in investing activities by $72.8 million, and therefore further concluded that the previously reported information should no longer be relied upon. As a result, we restated our unaudited Condensed Consolidated Statement of Comprehensive Income, Condensed Consolidated Balance Sheet, Condensed Consolidated Statement of Cash Flows, Condensed Consolidated Statement of Changes in Stockholders' Equity and related notes, for and as of the three months ended March 31, 2015. This restatement is included in Note 20, Restatement of Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) to the unaudited interim Condensed Consolidated Financial Statements included in our 2016 Q1 Form 10-Q, incorporated by reference herein. The error had no impact on the net decrease in cash and cash equivalents for the quarter ended March 31, 2015 and cash balances as of March 31, 2015. Except as previously disclosed, these restatements had no impact on prior periods.

As previously disclosed in our 2016 Q2 Form 10-Q, 2016 Q1 Form 10-Q and our 2015 Annual Report, due to material weaknesses in our internal control over financial reporting, our disclosure controls and procedures were not effective beginning as of December 31, 2015. These material weaknesses, which are more fully described in our 2015 Annual Report, relate to insufficient complement of personnel with an appropriate level of accounting knowledge, experience and training commensurate with our financial reporting requirements. Our management is actively engaged in implementing the remediation initiatives described in our 2015 Annual Report and 2016 Q1 Form 10-Q which are designed to address these material weaknesses. As indicated in our 2016 Q1 Form 10-Q, we completed the implementation of a global tax reporting system during the first quarter of 2016. As indicated in our 2016 Q2 Form 10-Q, during the second quarter of 2016, we continued our remediation efforts towards the following actions, which were previously described in the 2016 Q1 Form 10-Q and which remain on-going as of the date of this prospectus supplement:

- implementation of a global consolidation and planning system;
- implementation of control processes relating to newly-acquired businesses and non-routine transactions;
- implementation of enhanced monitoring controls relating to the financial reporting and performance of our newly-acquired businesses;
- implementation of enhanced financial planning and analysis function within our businesses and at the corporate level;
- addition of further qualified resources to our corporate and segment staff;
- enhancement of the controllership function in our newly-acquired businesses; and
- continued recruiting efforts to hire qualified personnel.

While significant progress has been made, additional time is needed to fully implement and demonstrate the effectiveness of the remediation initiatives and until remediated, the material weaknesses described above could result in material misstatements of our annual or interim consolidated financial statements that would not be prevented or detected. We are committed to operating effective controls, and management continues to regularly assess the progress and sufficiency of the ongoing initiatives and make adjustments as and when necessary.

Risks Relating to Our Business

Our business is subject to a number of risks of which you should be aware before you decide to invest in our common stock. In particular, you should consider the following risks, which are discussed more fully in this prospectus supplement as well as our 2015 Annual Report and 2016 Q2 Form 10-Q, both incorporated by reference in this prospectus supplement and the accompanying prospectus:

- our business model depends on our ability to consummate future acquisitions and to successfully integrate acquisitions into our business;
- our substantial indebtedness may adversely affect our cash flow and our ability to operate our business and fulfill our obligations under our indebtedness;
-

our business, results of operations and financial conditions depend on our ability to attract and retain key personnel, including our executive officers, and to effectively manage succession;

- the accuracy and timeliness of our financial reporting depends on our ability to remediate our existing material weaknesses in our internal control over financial reporting;

- maintaining an effective internal control environment with operations in multiple international locations, including language differences, varying levels of U.S. GAAP expertise in international locations and multiple financial information systems may present certain challenges;
- our existing material weaknesses may require the restatement of previously issued financial statements for additional periods;
- foreign exchange controls or other currency restrictions and limitation on the movement of funds, including the prohibition of the repatriation of funds, may result in adverse tax consequences and tax inefficiencies;
- our business and results of operations depend on our ability to protect and preserve our intellectual property rights;
- adverse weather conditions, business cycles as well as seasonality, may cause fluctuation in the revenue and operating results of our Agricultural Solutions business;
- conditions in the global economy, as well as social, political or economic instability, acts of wars and terrorism and natural disasters or other crisis may directly adversely affect our substantial international operations and financial condition;
- failure to comply with the FCPA and other similar anti-corruption laws could subject us to penalties and damage our reputation;
- agrochemical products are highly regulated by governmental agencies in countries where we do business; and
- our business involves chemicals manufacturing, which is both inherently hazardous and subject to evolving laws and regulations (including, but not limited to, the June 2016 amendments to the U.S. Toxic Substances Control Act and the EU REACH Substances of Very High Concern program) that could result in material costs relating to regulatory compliance, liabilities or litigation proceedings or other impacts, such as restrictions or prohibitions on our products.

These risks, among others, may have a material adverse effect on our business, financial condition or results of operations, which could cause the trading price of our shares of common stock to decline and result in a loss of all or a portion of your investment.

Corporate Information

Our principal office is located at 1450 Centrepark Boulevard, Suite 210, West Palm Beach, Florida 33401, and our telephone number at that address is (561) 207-9600. We maintain a website at www.platformspecialtyproducts.com where general information about us is available. Information on, or accessible through, our website is not part of this prospectus supplement.

THE OFFERING

The summary below is not intended to be complete. For a more detailed description of our common stock, see "Description of Capital Stock - Common Stock" in the accompanying prospectus.

Shares offered by us..	42,424,242Shares
Common Stock to be outstanding immediately after this offering..	272,057,150 shares (or 278,420,786 shares if the underwriters exercise in full their option to purchase additional shares) based upon 229,632,908 shares outstanding as of September 15, 2016.
Option to purchase additional shares................	We have granted the underwriters a 30-day option to purchase up to 6,363,636 additional shares of our common stock.
Use of proceeds..	We intend to use the net proceeds from this offering for general corporate purposes, including, but not limited to, the alternative settlement of certain obligations relating to our Series B Convertible Preferred Stock. See "Use of Proceeds."
Dividend policy..	We have never paid any cash dividends on our common stock. We intend to retain earnings to fund our working capital needs and growth opportunities and do not intend to pay any cash dividends. Holders of shares of our Series A preferred stock (the "Series A Preferred Stock") are entitled to receive an annual stock dividend based on the appreciated stock price compared to the highest dividend price previously used in calculating the Series A Preferred Stock dividends. No dividend may be declared on any other series of preferred stock, other than the Series A Preferred Stock, or common stock without the prior approval of a majority of the holders of the shares of our Series B Convertible Preferred Stock.
Market for our common stock..........................	Our shares of common stock are currently listed on the NYSE.
NYSE ticker symbol..	"PAH"
Risk Factors..	Investing in our common stock involves substantial risks. You should carefully consider all the information included or incorporated by reference in this prospectus supplement prior to investing in our common stock. In particular, we urge you to carefully consider the factors set forth under "Risk Factors" beginning on page S-24 of this prospectus supplement, page 4 of the accompanying prospectus and in the documents incorporated by reference herein and therein.

Unless otherwise indicated, the information presented in this prospectus supplement:

- assumes no exercise by the underwriters of their option to purchase up to 6,363,636 additional shares of our common stock; and
- excludes, in reference to the number of shares of common stock outstanding after this offering, (i) 2,000,000 shares of our common stock issuable upon the conversion of shares of Series A Preferred Stock; (ii) 22,107,590 shares of our common stock issuable upon the conversion of shares of Series B Convertible Preferred Stock, (iii) 7,997,665 shares of our common stock issuable upon exchange of shares of common stock of our subsidiary, Platform Delaware Holdings, Inc.; (iv) 565,198 shares of our common stock issuable upon exercise of options; (v) 12,387,681 shares of our common stock currently available for issuance under our Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (the "2013 Plan") (subject to increase in accordance with the terms of such plan), (vi) 2,348,687 shares of our common stock underlying restricted stock units ("RSUs") issued under the 2013 Plan; and (vii) 5,026,150 shares of common stock currently available for issuance under our Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan (the "2014 ESPP").

SUMMARY FINANCIAL DATA

The following table presents summary consolidated historical financial data for us and our Predecessor as of the dates and for each of the periods indicated. The summary consolidated historical data for the Successor 2015 Period, the Successor 2014 Period and the Successor 2013 Period and as of December 31, 2015, 2014 and 2013 have been derived from our audited consolidated financial statements incorporated by reference in this prospectus supplement and the accompanying prospectus. The summary consolidated historical data for our Predecessor 2013 Period has been derived from the audited consolidated financial statements of our Predecessor incorporated by reference in this prospectus supplement and the accompanying prospectus. The summary consolidated historical data for the Successor 2016 Six Month Period and as of June 30, 2016 and the Successor 2015 Six Month Period and as of June 30, 2015, have been derived from our unaudited condensed consolidated interim financial statements incorporated by reference in this prospectus supplement and the accompanying prospectus. The summary consolidated historical financial data for such interim periods contain all normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of the financial information set forth in those statements.

The summary comparable financial data for the six months ended June 30, 2016 and the last twelve months ended June 30, 2016 give effect to the Alent, OMG and OMG Malaysia Acquisitions and the related financings as if they had been consummated on January 1, 2015. The summary financial data included in this section is not necessarily indicative of future results and should be read in conjunction with "Capitalization" as well as the financial statements of Platform, Arysta and Alent and the pro forma financial information filed with respect to such acquisitions, and the respective notes thereto, in each case, incorporated by reference in this prospectus supplement and the accompanying prospectus.

In this section, we present comparable net (loss) income available to common stockholders, comparable sales, comparable cost of sales, comparable gross profit, Adjusted EBITDA, Adjusted EBITDA margin, segment comparable Adjusted EBITDA and segment comparable sales, which are non-GAAP financial measures. Alent's and the OM Businesses' methods of calculating their Adjusted EBITDA differed from our method of calculating Adjusted EBITDA and, as a result, the financial information and synergies included or incorporated by reference herein may not be comparable and/or indicative of our future results of operations. As such, you are cautioned not to place undue reliance on this information. For definitions of these non-GAAP financial measures and reconciliations to the most comparable GAAP financial measure, please refer to the applicable reconciliation tables and " - Definitions of Non-GAAP Financial Measures" included in this section.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Predecessor	Successor	Combined Successor and Predecessor (Non-GAAP)	Successor			
(amounts in millions)	Period from January 1, 2013 to October 31, 2013	Period from Inception (April 23, 2013) to December 31, 2013	Year Ended December 31, 2013	Year Ended December 31, 2014	Year Ended December 31, 2015	Six Months Ended June 30, 2015	Six Months Ended June 30, 2016
Statement of Operations Data							
Net sales	$627.7	$118.2	$746.0	$843.2	$2,542.3	$1,209.9	$1,745.4
Cost of sales	304.9	82.5	366.8	446.6	1,550.4	734.2	1,008.8
Gross profit	322.8	35.7	379.2	396.6	991.9	475.7	736.6
Total operating expenses	231.1	231.3	275.5	387.1	920.3	429.5	589.6
Operating profit (loss)	91.7 [1]	(195.6) [2]	103.7	9.5 [3]	71.6 [4]	46.2 [5]	147.0 [6]
Other expense	(65.2)	(5.8)	(49.9)	(40.4)	(300.9)	(57.1)	(244.1)
Income (loss) before income taxes, non-controlling interests and dividends on preferred shares	26.5 [1]	(201.4) [2]	53.8	(30.9) [3]	(229.3) [4]	(10.9) [5]	(97.1) [6]
Income tax (expense)benefit	(13.0)	5.8	(23.2)	6.7	(75.1)	(24.5)	(45.3)
Net income (loss)	13.5 [1]	(195.6) [2]	30.6	(24.2) [3]	(304.4) [4]	(35.4) [5]	(142.4) [6]
Net (income) loss attributable to non-controlling interests	(0.3)	1.4	0.2	(5.7)	(4.2)	(3.5)	(1.2)
Net income (loss) attributable to stockholders	13.2	(194.2)	30.8	(29.9)	(308.6)	(38.9)	(143.6)
Accrued stock dividend on Founder's preferred shares	—	—	—	(232.7)	—	—	—
Accrued payment-in-kind dividend on	(22.4)	—	—	—	—	—	—

cumulative preferred shares							
Net income (loss) attributable to common stockholders	$(9.2)	$(194.2)	$ 30.8	$(262.6)	$(308.6)	$(38.9)	$(143.6)
Other Financial Data							
Adjusted EBITDA(*)	$152.7	$27.4		$212.2	$567.7	$299.8	$361.3

* For a definition of "Adjusted EBITDA," please refer to "Summary Financial Data - Definition of Non-GAAP Financial Measures" below.

CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

(amounts in millions)	Successor As of December 31, 2013	As of December 31, 2014	As of December 31, 2015	As of June 30, 2016
Balance Sheet Data				
Cash and cash equivalents	$ 123.0	$ 397.3	$ 432.2	$ 341.7
Restricted cash	—	600.0	0.3	0.9
Working capital (*)	263.8	1,335.8	1,208.1	1,132.3
Total assets	2,258.5	4,547.3	10,190.2	10,672.0
Total debt	750.6	1,405.6	5,228.3	5,348.7
Redeemable preferred stock - Series B	—	—	645.9	645.9
Total equity	1,115.1	2,552.6	2,273.3	2,567.9

(*) Working capital is defined as current assets less current liabilities.

Comparability of the tables above is affected by the following acquisitions: OMG Malaysia in January 2016, Alent in December 2015, OMG in October 2015, Arysta in February 2015, CAS in November 2014, Agriphar in October 2014, and MacDermid in October 2013.

(1) The results presented include the following significant items affecting comparability in the Predecessor 2013 Period:

- transaction costs of $16.9 million, primarily comprised of professional fees and fees paid to the Predecessor's stockholders resulting from management fees payable in conjunction with the MacDermid Acquisition; and
- deemed compensation expense related to pre-acquisition share awards of approximately $9.3 million.

(2) The results presented include the following significant items affecting comparability in the Successor 2013 Period:

- non-cash charge related to the Series A Preferred Stock dividend rights of $172.0 million;
- purchase accounting adjustment of $23.9 million charged to cost of sales for the manufacturer’s profit in inventory adjustment; and
- transaction costs, primarily comprised of professional fees of $15.2 million.

(3) In addition to the consolidation impact of the 2014 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability in the Successor 2014 Period:

- purchase accounting adjustment of $35.5 million charged to cost of sales for the manufacturer’s profit in inventory adjustment;
- non-cash fair value adjustment to long-term contingent consideration costs of $29.1 million; and
- acquisition-related costs, including restructuring and integration of $47.8 million.

(4) In addition to the consolidation impact of the 2015 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability in the Successor 2015 Period:

- purchase accounting adjustment of $76.5 million charged to cost of sales for the manufacturer’s profit in inventory adjustment;
- acquisition-related costs, including restructuring and integration costs of $147.7 million;
- loss on foreign exchange contracts of $73.7 million related to the hedging of the purchase price in the Alent Acquisition.

(5) The results presented include the following significant items affecting comparability in the Successor Six Month 2015 Period:

- purchase accounting adjustment of $56.7 million charged to cost of sales for the manufacturer’s profit in inventory adjustment;
- acquisition-related costs, including restructuring and integration costs of $69.1 million; and
- a favorable legal settlement of $16.0 million.

(6) In addition to the consolidation impact of the 2015 and 2016 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability in the Successor Six Month 2016 Period:

- purchase accounting adjustment of $11.7 million charged to cost of sales for the manufacturer’s profit in inventory adjustment; and
- acquisition-related costs, including restructuring and integration costs of $36.4 million.

RECONCILIATION OF NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS TO ADJUSTED EBITDA (NON-GAAP)
(Unaudited)
The following table reconciles Net loss attributable to common stockholders to Adjusted EBITDA for the periods indicated below. For a definition of "Adjusted EBITDA," please refer to "Summary Financial Data - Definition of Non-GAAP Financial Measures" below.

	Predecessor	Successor				
(amounts in millions)	Period from January 1, 2013 to October 31, 2013	Period from Inception (April 23, 2013) to December 31, 2013	Year Ended December 31, 2014	Year Ended December 31, 2015	Six Months Ended June 30, 2015	Six Months Ended June 30, 2016
Net loss attributable to common stockholders	$(9.2)	$(194.2)	$(262.6)	$(308.6)	$(38.9)	$(143.6)
Net income attributable to the non-controlling interests	0.3	(1.4)	5.7	4.2	3.5	1.2
Income tax expense (benefit)	13.0	(5.8)	(6.7)	75.1	24.5	45.3
Net income (loss) before income taxes and non-controlling interests	4.1	(201.4)	(263.6)	(229.3)	(10.9)	(97.1)
Adjustments to reconcile to Adjusted EBITDA:						
Interest expense, net	45.9	5.4	37.9	213.9	90.5	191.2
Depreciation and amortization expense	32.8	12.8	88.0	251.0	114.2	168.0
Accrued payment-in-kind dividend on cumulative preferred shares	22.4	—	—	—	—	—
Acquisition and integration costs	16.9 (1)	15.2 (1)	47.8 (1)	92.9 (1)	55.4 (1)	24.2 (1)
Debt extinguishment	18.8 (2)	—	—	—	—	—
Non-cash charges related to preferred dividend rights	—	172.0 (3)	—	—	—	—
Accrued stock dividend on Founder's preferred shares	—	—	232.7 (3)	—	—	—
Manufacturer’s profit in inventory purchase accounting adjustments	—	23.9 (4)	35.5 (4)	76.5 (4)	56.7 (4)	11.7 (4)
Non-cash change in fair value of contingent consideration	—	(0.7) (5)	29.1 (5)	6.8 (5)	3.6 (5)	4.1 (5)
Foreign exchange losses (gains) on foreign denominated external and	—	—	1.1 (6)	46.4 (6)	(6.1) (6)	46.8 (6)

internal debt						
Fair value loss on foreign exchange forward contract	—	—	—	73.7 (7)	—	—
Restructuring expenses	4.5	3.5 (8)	3.0 (8)	54.8 (8)	13.7 (8)	12.2 (8)
Legal settlements	—	—	—	(16.0) (9)	(16.0) (9)	(2.8) (9)
Long-term compensation issued in connection with acquisitions	9.3	0.5 (10)	1.3 (10)	0.1	1.7 (10)	0.4 (10)
Other	(2.0)	(3.8)	(0.6)	(3.1)	(3.0)	2.6
Adjusted EBITDA	$152.7	$27.4	$212.2	$567.7	$299.8	$361.3

(1) Adjustment for costs associated with acquisitions, including costs of obtaining related financing such as investment banking, legal, and accounting fees, transfer taxes, costs associated with an investigation related to certain past business practices of Arysta, an acquired company, costs of integrating acquisitions, and bonuses paid to a member of management of an acquired company related to completed acquisitions. The Company adjusts these costs because they are not reflective of ongoing operations.
(2) Adjustment to reverse debt extinguishment charge in connection with debt incurred as a result of the Predecessor's recapitalization
(3) Adjustment for non-cash charge related to the Series A Preferred Stock dividend rights in connection with the MacDermid Acquisition.
(4) Adjustment for purchase accounting fair value adjustment to inventory associated with acquisitions charged to cost of sales. The Company adjusts these costs because they are not reflective of ongoing operations.
(5) Adjustment for the change in fair value of the contingent consideration in connection with the MacDermid Acquisition. The Company adjusts these costs because they are not reflective of ongoing operations.
(6) Adjustment for foreign exchange gains and losses on intercompany and third-party long-term debt because these currencies are out of its control, are expected to offset on a long-term basis and, due to their long-term nature, are not fully realized. The Company does not exclude foreign exchange gains and losses on short-term intercompany and third-party payables and receivables with third parties.
(7) Adjustment to reverse loss on economic hedges related to the Alent Acquisition.
(8) Adjustment for cost of restructuring acquired businesses. The Company adjusts these costs because they are not reflective of ongoing operations.
(9) Adjustment to reverse gain on legal settlement, including reimbursement of legal fees.
(10) Adjustment for the portion of long-term compensation plans associated with the Performance Solutions Acquisitions for 2016 and the Agricultural Solutions Acquisitions for 2015. The Company adjusts these costs because they are not reflective of ongoing operations. The Company does not adjust for the cost of non-acquisition related ongoing long-term compensation plans.

RECONCILIATION OF NET (LOSS) INCOME AVAILABLE TO COMMON STOCKHOLDERS
TO ADJUSTED EBITDA (NON-GAAP)
(Unaudited)

The following tables contain unaudited comparable financial information which assumes full period contribution of all our acquired businesses to date. This information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had our Prior Acquisitions been completed as of the dates indicated, or that may be achieved in the future. Historical financial results and information included herein relating to these acquired businesses were derived from public filings, when applicable, and/or information provided by management of these businesses prior to their acquisitions by Platform. In addition, financial information for some of these acquired businesses were historically prepared in accordance with non-GAAP accounting methods and may or may not be comparable to our financial statements. Consequently, you are cautioned not to place undue reliance on these results and information as they may not be representative of our actual and future results as a consolidated company. For definitions of Adjusted EBITDA and comparable Adjusted EBITDA, please refer to "Summary Financial Data - Non-GAAP Definitions" below.

	Year ended December 31, 2015								
(amounts in millions)	Platform (Historical)		Arysta (Historical) for the period from January 1, 2015 to February 12, 2015		Alent (Historical) for the eleven months ended November 30, 2015	(*)	OM (Historical) for the ten months ended October 31, 2015	OM Malaysia (Historical) for the twelve months ended December 31,2015	Comparable Platform (Non-GAAP)
Net sales	$2,542.3		$ 87.5		$ 847.8		$ 103.8	$ 38.6	$ 3,620.0
Cost of sales	1,550.4		54.0		499.3		68.7	24.3	2,196.7
Gross profit	$991.9		$ 33.5		$ 348.5		$ 35.1	$ 14.3	$ 1,423.3
Net (loss) income available to common stockholders	$(308.6)		$ (64.9)		$ 54.5		$ 2.4	$ 10.0	$ (306.6)
Adjustments to reconcile to Adjusted EBITDA:									
Net income attributable to the non-controlling interests	$4.2		$ 0.1		$ —		$ —	$ —	$ 4.3
Income tax expense (benefit)	75.1		(2.5)		17.3		1.6	2.9	94.4
Interest expense, net	213.9		48.3		7.0		(0.1)	—	269.1
Depreciation and amortization expense	251.0		10.1		14.1		8.0	0.3	283.5
Acquisition and integration costs	92.9	(1)	—		—		—	—	92.9
Manufacturer's profit in inventory purchase accounting adjustments	76.5	(2)	—		—		—	—	76.5
Non-cash change in fair value of contingent consideration	6.8		—		—		—	—	6.8
Foreign exchange losses (gains) on foreign denominated	46.4	(3)	12.8	(3)	(2.8)	(3)	—	—	56.4

external and internal debt						
Fair value loss on foreign exchange forward contract	73.7 (4)	—	—	—	—	73.7
Restructuring expenses	54.8 (5)	1.3 (5)	6.2 (5)	2.7 (5)	—	65.0
Legal settlements	(16.0) (6)	—	—	—	—	(16.0)
Long-term compensation issued in connection with acquisitions	0.1	—	1.1	—	—	1.2
Corporate development costs	—	—	47.4	—	—	47.4
Share of joint venture income	—	—	(1.8)	—	—	(1.8)
Other	(3.1)	(2.2)	0.1	—	—	(5.2)
Adjusted EBITDA (7)	$ 567.7	$ 3.0	$ 143.1	$ 14.6	$ 13.2	$ 741.6

(1) Adjustment for costs associated with acquisitions, including costs of obtaining related financing such as investment banking, legal, and accounting fees; transfer taxes; and bonuses paid to a member of management of an acquired company related to the completion the Arysta Acquisition. The Company adjusts these costs because they are not reflective of ongoing operations.
(2) Adjustment for purchase accounting fair value adjustment to inventory associated with acquisitions charged to cost of sales primarily related to the Agricultural Solutions Acquisitions. The Company adjusts these costs because they are not reflective of ongoing operations.
(3) Adjustment for foreign exchange gains and losses on intercompany and third-party long-term debt because these currencies are out of its control, are expected to offset on a long-term basis and, due to their long-term nature, are not fully realized. The Company does not exclude foreign exchange gains and losses on short-term intercompany and third-party payables and receivables with third parties.
(4) Adjustment to reverse loss on economic hedges related to the Alent Acquisition.
(5) Adjustment for cost of restructuring acquired businesses in both the Agricultural Solutions and Performance Solutions segments. The Company adjusts these costs because they are not reflective of ongoing operations.
(6) Adjustment to reverse gain on legal settlement including reimbursement of legal fees.
(7) The twelve months ended December 31, 2015 Adjusted EBITDA results include synergies that were achieved as a result of businesses in our Agricultural Solutions Segment of $38 million, of which $13 million occurred in the first half of 2015 Excluded from this measure are anticipated synergies that may be achieved of approximately $42 million in the Agricultural Solutions segment (to be phased in by the end of 2017) and approximately $70 million in the Performance Solutions segment (to be phased in over a period of three years).
(*) Reconciliation to Alent's historical financial statements for the nine months ended September 30, 2015 appears on the following page.

(amounts in millions)	Pound Sterling Alent (Historical)as issued for the nine months ended Sept 30, 2015	Alent (Historical)Two months ended November 30 2015	Alent Adjustments	Alent (Historical) for the eleven months ended November 30, 2015	U.S. Dollars Converted from Pound Sterling to U.S. Dollars (1)	Classification in accordance with GAAP
Revenue	£453.5	£ 100.1	£ —	£ 553.6	$ 847.8	Net Sales
Manufacturing cost before exceptional items	(268.1)	(57.9)	—	(326.0)	(499.3)	Cost of Sales
Administration, selling and distribution cost before exceptional items	(116.1)	(26.7)	(1.1)	(143.9)	(199.3)	STG&A
					(21.2)	Research and development
Operating profit before exceptional items	69.3	15.5	(1.1)	83.7	128.0	
Exceptional items	(10.2)	(24.8)	—	(35.0)	(0.6)	STG&A
					(5.3)	STG&A
					(47.4)	STG&A
Operating profit	59.1	(9.3)	(1.1)	48.7	74.7	
			1.7	1.7	2.6	Other
Share of post-tax profit of joint ventures	0.6	0.5	—	1.1	1.8	Other
Finance costs	(4.0)	(0.8)	—	(4.8)	(6.3)	Interest, net
					(1.3)	STG&A
Finance income	0.2	—	—	0.2	0.3	Interest, net
Profit before tax	55.9	(9.6)	0.6	46.9	71.8	
Income tax costs - ordinary activities	(19.6)	(11.5)	0.6	(30.5)	(46.7)	Income tax benefit (provision)
Income tax costs - exceptional items	17.4	1.8	—	19.2	29.4	Income tax benefit (provision)
Profit for the period	£53.7	£ (19.3)	£ 1.2	£ 35.6	$ 54.5	
Adjustments to reconcile to Adjusted EBITDA:						
Income tax costs - ordinary activities of £19.6 net of Income tax costs - exceptional items of £(17.4)	£2.2	£ 9.7	£ (0.6)	£ 11.3	$ 17.3	Income tax expense (benefit)
Finance costs of £4.0, net of Finance income of £0.2	3.8	0.8	—	4.6	7.0	Interest expense, net
Depreciation	6.8	1.4	1.0	9.2	14.1	Depreciation and amortization expense
			(1.8)	(1.8)	(2.8)	Foreign exchange losses (gains) on foreign denominated external and

						internal debt
Restructuring charges	3.0	1.1	(0.3)	3.8	6.2	Restructuring expenses
Litigation settlements	(0.7)	—	0.7	—	—	Legal settlements
Equity based compensation	—	0.2	0.5	0.7	1.1	Long-term compensation issued in connection with acquisitions
Corporate development charges	7.9	23.7	(0.4)	31.2	47.4	Corporate development costs
Share of post-tax profit of joint ventures	(0.6)	(0.5)	—	(1.1)	(1.8)	Share of joint venture income
Other	0.5	—	(0.4)	0.1	0.1	Other
Adjusted EBITDA	£76.6	£ 17.1	£ (0.1)	£ 93.6	$ 143.1	

(1) Amounts were calculated utilizing a blended Pound Sterling to U.S. Dollar exchange rate of 1.5156, 1.5334 and 1.5489 for the three month periods ended March 31, 2015, June 30, 2015 and September 30, 2015, respectively, and a blended rate of 1.5168 for the two month period ended November 30, 2015.

	Last Twelve Months Ended June 30, 2016				
(amounts in millions)	Platform Historical for the Last twelve months ended 6/30/16	Alent for the period 7/1/15 to 12/2/15 (*)	OM for the period 7/1/15 to 10/27/15	OM Malaysia for the period 7/1/15 to 1/31/16	Comparable Platform (Non-GAAP)
Net Sales	$3,077.8	$379.6	$ 41.4	$ 18.3	$ 3,517.1
Cost of sales	1,825.0	221.4	29.2	11.2	2,086.8
Gross profit	$1,252.8	$158.2	$ 12.2	$ 7.1	$ 1,430.3
Net (loss) income available to common stockholders	$(413.3)	$(15.4)	$ 3.6	$ 5.0	$ (420.1)
Adjustments to reconcile to Adjusted EBITDA:					
Net income attributable to the non-controlling interests	$1.9	$—	$ —	$ —	$ 1.9
Income tax expense (benefit)	95.9	23.1	0.9	1.5	121.4
Interest expense, net	314.6	3.2	(0.1)	—	317.7
Depreciation and amortization expense	304.8	6.5	3.2	0.2	314.7
Acquisition and integration costs	61.7 (1)	—	—	—	61.7
Manufacturer's profits in inventory purchase accounting adjustments	31.5 (2)	—	—	—	31.5
Non-cash change in fair value of contingent consideration	7.3	—	—	—	7.3
Foreign exchange losses (gains) on foreign denominated external and internal debt	99.3 (3)	2.8 (3)	—	—	102.1
Fair value loss on foreign exchange forward contract	73.7 (4)	—	—	—	73.7
Restructuring expenses	53.3 (5)	3.4 (5)	0.7 (5)	—	57.4
Legal settlements	(2.8) (6)	—	—	—	(2.8)
Long-term compensation issued in connection with acquisitions	(1.2)	0.6	—	—	(0.6)
Corporate development costs	—	45.0	—	—	45.0
Share of joint venture income	—	(1.3)	—	—	(1.3)
Other	2.5	(0.5)	—	—	2.0
Adjusted EBITDA (7)	$629.2	$67.4	$ 8.3	$ 6.7	$ 711.6

(1) Adjustment for costs associated with acquisitions, including costs of obtaining related financing such as investment banking, legal, and accounting fees; transfer taxes; costs associated with an investigation related to certain past business practices of Arysta, an acquired company, and costs of integrating acquisitions; and bonuses paid to a member of management of an acquired company related to the completion the Arysta Acquisition. The Company adjusts these costs because they are not reflective of ongoing operations.
(2) Adjustment for purchase accounting fair value adjustment to inventory associated with acquisitions charged to cost of sales primarily related to the Agricultural Solutions Acquisitions. The Company adjusts these costs because they are not reflective of ongoing operations
(3) Adjustment for foreign exchange gains and losses on intercompany and third-party long-term debt because these currencies are out of its control, are expected to offset on a long-term basis and, due to their long-term nature, are not

fully realized. The Company does not exclude foreign exchange gains and losses on short-term intercompany and third-party payables and receivables with third parties.

(4) Adjustment to reverse loss on economic hedges related to the Alent Acquisition.

(5) Adjustment for cost of restructuring acquired businesses in both the Agricultural Solutions and Performance Solutions segments. The Company adjusts these costs because they are not reflective of ongoing operations.

(6) Adjustment to reverse gain on legal settlement including reimbursement of legal fees.

(7) The last twelve months ended June 30, 2016 Adjusted EBITDA results include synergies that were achieved as a result of combination of businesses in our (i) Agricultural Solutions Segment of $39 million, and in our (ii) Performance Solutions Segment of $11 million. Excluded from this measure are anticipated synergies that may be achieved of approximately $28 million in the Agricultural Solutions segment (to be phased in by the end of 2017) and approximately $59 million in the Performance Solutions segment (to be phased in over a period of three years).

(*) Reconciliation to Alent's historical financial statements for the nine months ended September 30, 2015 and the six months ended June 30, 2015 appears on the following page.

(amounts in millions)	Pound Sterling						U.S. Dollars	
	Alent (Historical) as issued for the nine months ended Sept 30, 2015	Alent (Historical) as issued for the six months ended June 30, 2015	Three months ended Sept 30, 2015	Alent (Historical) Two months ended November 30 2015	Alent Adjustments	Alent (Historical) for the period 7/1/15 to 11/30/15	Converted from Pound Sterling to U.S. Dollars (1)	Classification in accordance with GAAP
Revenue	£453.5	£ 307.1	£146.4	£ 100.1	£ —	£ 246.5	$ 379.6	Net Sales
Manufacturing cost before exceptional items	(268.1)	(182.3)	(85.8)	(57.9)	—	(143.7)	(221.4)	Cost of Sales
Administration, selling and distribution cost before exceptional items	(116.1)	(79.8)	(36.3)	(26.7)	(0.5)	(63.5)	(88.6)	STG&A
							(9.3)	R&D
Operating profit before exceptional items	69.3	45.0	24.3	15.5	(0.5)	39.3	60.3	
Exceptional items	(10.2)	(3.4)	(6.8)	(24.8)	—	(31.6)	(0.6)	STG&A
							(2.5)	STG&A
							(45.0)	STG&A
Operating profit	59.1	41.6	17.5	(9.3)	(0.5)	7.7	12.2	
					(1.5)	(1.5)	(2.4)	Other
Share of post-tax profit of joint ventures	0.6	0.3	0.3	0.5	—	0.8	1.3	Other
Finance costs	(4.0)	(2.6)	(1.4)	(0.8)	—	(2.2)	(2.9)	Interest, net
							(0.7)	STG&A
Finance income	0.2	0.1	0.1	—	—	0.1	0.2	Interest, net
Profit before tax	55.9	39.4	16.5	(9.6)	(2.0)	4.9	7.7	
Income tax costs - ordinary activities	(19.6)	(12.7)	(6.9)	(11.5)	0.1	(18.3)	(28.0)	Income tax
Income tax costs - exceptional items	17.4	16.0	1.4	1.8	—	3.2	4.9	Income tax
Profit for the period	£53.7	£ 42.7	£11.0	£ (19.3)	£ (1.9)	£ (10.2)	$ (15.4)	
Adjustments to reconcile to Adjusted EBITDA:								
Income tax costs - ordinary activities of £19.6 net of Income tax costs - exceptional items of £(17.4) for the nine months ended September 30, 2015 and £12.7 and £(16.0), respective for the six months ended June 30, 2015	£2.2	£ (3.3)	£5.5	£ 9.7	£ (0.1)	£ 15.1	$ 23.1	Income tax expense (benefit)
	3.8	2.5	1.3	0.8	—	2.1	3.2	

Finance costs of £4.0, net of Finance income of £0.2 for the nine months ended September 30, 2015 and £2.6 and £0.1, respective for the six months ended June 30, 2015								Interest expense, net
Depreciation	6.8	4.6	2.2	1.4	0.6	4.2	6.5	Depreciation and amortization expense
					1.8	1.8	2.8	Foreign exchange losses on foreign denominated external and internal debt
Restructuring charges	3.0	1.7	1.3	1.1	—	2.4	3.4	Restructuring expenses
Litigation settlements	(0.7)	(0.7)	—	—	—	—	—	Legal settlements
Equity based compensation	—	—	—	0.2		0.2	0.6	Long-term compensation issued in connection with acquisitions
Corporate development charges	7.9	2.4	5.5	23.7	—	29.2	45.0	Corporate development costs
Share of post-tax profit of joint ventures	(0.6)	(0.3)	(0.3)	(0.5)	—	(0.8)	(1.3)	Share of joint venture income
Other	0.5	0.3	0.2	—	(0.3)	(0.1)	(0.5)	Other
Adjusted EBITDA	£76.6	£ 49.9	£26.7	£ 17.1	£ 0.1	£ 43.9	$ 67.4	

(1) Amounts were calculated utilizing a blended Pound Sterling to U.S. Dollar exchange rate of 1.5156, 1.5334 and 1.5489 for the three month periods ended March 31, 2015, June 30, 2015 and September 30, 2015, respectively, and a blended rate of 1.5168 for the two month period ended November 30, 2015.

(amounts in millions)	Six Months Ended June 30, 2015 Platform Historical for the six months ended 6/30/15		Arysta for the period 1/1/15 to 2/13/15		Alent for the period 1/1/15 to 6/30/15	(*)	OM for the period 1/1/15 to 6/30/15		OM Malaysia for the period 1/1/15 to 6/30/15	Comparable Platform (Non-GAAP)
Net sales	$1,209.9		$87.5		$468.2		$62.4		$ 20.3	$ 1,848.3
Cost of sales	734.2		54.0		277.9		39.5		13.1	1,118.7
Gross profit	$475.7		$33.5		$190.3		$22.9		$ 7.2	$ 729.6
Net (loss) income available to common stockholders	$(38.9)		$(64.9)		$69.9		$(1.2)		$ 5.0	$ (30.1)
Adjustments to reconcile to Adjusted EBITDA:										
Net income attributable to the non-controlling interests	$3.5		$0.1		$—		$—		$ —	$ 3.6
Income tax expense (benefit)	24.5		(2.5)		(5.8)		0.7		1.4	18.3
Interest expense, net	90.5		48.3		3.8		—		—	142.6
Depreciation and amortization expense	114.2		10.1		7.6		4.8		0.1	136.8
Acquisition and integration costs	55.4	(1)	—		—		—		—	55.4
Manufacturer's profits in inventory purchase accounting adjustments	56.7	(2)	—		—		—		—	56.7
Non-cash change in fair value of contingent consideration	3.6		—		—		—		—	3.6
Foreign exchange losses (gains) on foreign denominated external and internal debt	(6.1)	(3)	12.8	(3)	(5.6)	(3)	—		—	1.1
Fair value loss on foreign exchange forward contract	—		—		—		—		—	—
Restructuring expenses	13.7	(4)	1.3	(4)	2.8	(4)	2.0	(4)	—	19.8
Legal settlements	(16.0)	(5)	—		—		—		—	(16.0)
Acquisition put option expiration	—		—		—		—		—	—
Long-term compensation issued in connection with acquisitions	1.7		—		0.5		—		—	2.2
Corporate development costs	—		—		2.4		—		—	2.4
Share of joint venture income	—		—		(0.5)		—		—	(0.5)
Other	(3.0)		(2.2)		0.6		—		—	(4.6)
Adjusted EBITDA (6)	$299.8		$3.0		$75.7		$6.3		$ 6.5	$ 391.3

(1) Adjustment for costs associated with acquisitions, including costs of obtaining related financing such as investment banking, legal, and accounting fees; transfer taxes; and bonuses paid to a member of management of an acquired company related to the completion the Arysta Acquisition. The Company adjusts these costs because they are not reflective of ongoing operations.

(2) Adjustment for purchase accounting fair value adjustment to inventory associated with acquisitions charged to cost of sales primarily related to the Agricultural Solutions Acquisitions. The Company adjusts these costs because they are not reflective of ongoing operations

(3) Adjustment for foreign exchange gains and losses on intercompany and third-party long-term debt because these currencies are out of its control, are expected to offset on a long-term basis and, due to their long-term nature, are not fully realized. The Company does not exclude foreign exchange gains and losses on short-term intercompany and third-party payables and receivables with third parties.
(4) Adjustment for cost of restructuring acquired businesses in both the Agricultural Solutions and Performance Solutions segments. The Company adjusts these costs because they are not reflective of ongoing operations.
(5) Adjustment to reverse gain on legal settlement including reimbursement of legal fees.
(6) The six month period ended June 30, 2015 Adjusted EBITDA results include synergies that were achieved as a result of combination of businesses in our Agricultural Solutions Segment of $13 million. Excluded from this measure are anticipated synergies that may be achieved of approximately $67 million in the Agricultural Solutions segment (to be phased in by the end of 2017) and approximately $70 million in the Performance Solutions segment (to be phased in over a period of three years).
(*) Reconciliation to Alent's historical financial statements for the six months ended June 30, 2015 appears on the following page.

(amounts in millions)	Pound Sterling Alent (Historical)as issued for the six months ended June 30, 2015	Alent Adjustments	Alent (Historical) for the six months ended June 30, 2015	U.S. Dollars Converted from Pound Sterling to U.S. Dollars (1)	Classification in accordance with GAAP
Revenue	£307.1	£ —	£ 307.1	$ 468.2	Net Sales
Manufacturing cost before exceptional items	(182.3)	—	(182.3)	(277.9)	Cost of Sales
Administration, selling and distribution cost before exceptional items	(79.8)	(0.6)	(80.4)	(110.7)	STG&A
				(11.9)	R&D
Operating profit before exceptional items	45.0	(0.6)	44.4	67.7	
Exceptional items	(3.4)	—	(3.4)	—	STG&A
				(2.8)	STG&A
				(2.4)	STG&A
Operating profit	41.6	(0.6)	41.0	62.5	
		3.2	3.2	5.0	Other
Share of post-tax profit of joint ventures	0.3	—	0.3	0.5	Other
Finance costs	(2.6)	—	(2.6)	(3.4)	Interest, net
				(0.6)	STG&A
Finance income	0.1	—	0.1	0.1	Interest, net
Profit before tax	39.4	2.6	42.0	64.1	
Income tax costs - ordinary activities	(12.7)	0.5	(12.2)	(18.7)	Income tax
Income tax costs - exceptional items	16.0	—	16.0	24.5	Income tax
Profit for the period	£42.7	£ 3.1	£ 45.8	$ 69.9	
Adjustments to reconcile to Adjusted EBITDA:					
Income tax costs - ordinary activities of £12.7 net of Income tax costs - exceptional items of £(16.0) for the six months ended June 30, 2015	£(3.3)	£ (0.5)	£ (3.8)	$ (5.8)	Income tax expense (benefit)
Finance costs of £2.6, net of Finance income of £0.1 for the six months ended June 30, 2015	2.5	—	2.5	3.8	Interest expense, net
Depreciation	4.6	0.4	5.0	7.6	Depreciation and amortization expense
		(3.6)	(3.6)	(5.6)	Foreign exchange losses (gains) on foreign denominated external and internal debt
Restructuring charges	1.7	0.1	1.8	2.8	Restructuring expenses
Litigation settlements	(0.7)	0.7	—	—	Legal settlements
Equity based compensation	—	0.3	0.3	0.5	

					Long-term compensation issued in connection with acquisitions
Corporate development charges	2.4	(0.8)	1.6	2.4	Corporate development costs
Share of post-tax profit of joint ventures	(0.3)	—	(0.3)	(0.5)	Share of joint venture income
Other	0.3	0.1	0.4	0.6	Other
Adjusted EBITDA	£49.9	£ (0.2)	£ 49.7	$ 75.7	

(1) Amounts were calculated utilizing a blended Pound Sterling to U.S. Dollar exchange rate of 1.5156 and 1.5334 for the three month periods ended March 31, 2015 and June 30, 2015, respectively.

RECONCILIATION OF REPORTED SEGMENT RESULTS TO
COMPARABLE SEGMENT RESULTS (NON-GAAP)
(Unaudited)
Reconciliation of reported Segment Sales to Comparable Segment Sales
The following table reconciles segment sales to comparable sales for the year ended December 31, 2015. For a definition of comparable sales, please refer to "Summary Financial Data - Non-GAAP Definitions" below.

(amounts in millions)	Year Ended December 31, 2015
Performance Solutions	$ 801
- Acquisitions:	
Alent	848
OM group	142
Performance Solutions Comparable Sales	1,791
Agricultural Solutions	1,741
- Acquisitions:	
Arysta	88
Agricultural Solutions Comparable Sales	1,829
Total Comparable Sales	$ 3,620

Reconciliation of reported Segment Adjusted EBITDA to Comparable Segment Adjusted EBITDA
The following table reconciles segment Adjusted EBITDA to comparable segment Adjusted EBITDA for the year ended December 31, 2015. For a definition of "Adjusted EBITDA" and "Comparable Adjusted EBITDA" please refer to "Summary Financial Data - Non-GAAP Definitions" below. For definitions of comparable Adjusted EBITDA and comparable Adjusted EBIDTA, please refer to "Summary Financial Data - Non-GAAP Definitions" below.

(amounts in millions)		Year Ended December 31, 2015
Performance Solutions		$ 224
- Acquisitions:		
Alent	(*)	143
OM group		28
- Corporate cost allocation		12
Performance Solutions Comparable Adj. EBITDA		$ 407
Agricultural Solutions		$ 343
- Acquisitions:		
Arysta		3
- Corporate cost allocation		36
Agricultural Solutions Comparable Adj. EBITDA		$ 382

(*) Reconciliation to Alent's historical financial statements for the nine months ended September 30, 2015 appears on the following page.

(amounts in millions)	Pound Sterling Alent (Historical)as issued for the nine months ended Sept 30, 2015	Alent (Historical)Two months ended November 30 2015	Alent Adjustments	Alent (Historical) for the eleven months ended November 30, 2015	U.S. Dollars Converted from Pound Sterling to U.S. Dollars (1)	Classification in accordance with GAAP
Revenue	£453.5	£ 100.1	£ —	£ 553.6	$ 847.8	Net Sales
Manufacturing cost before exceptional items	(268.1)	(57.9)	—	(326.0)	(499.3)	Cost of Sales
Administration, selling and distribution cost before exceptional items	(116.1)	(26.7)	(1.1)	(143.9)	(199.3)	STG&A
					(21.2)	Research and development
Operating profit before exceptional items	69.3	15.5	(1.1)	83.7	128.0	
Exceptional items	(10.2)	(24.8)	—	(35.0)	(0.6)	STG&A
					(5.3)	STG&A
					(47.4)	STG&A
Operating profit	59.1	(9.3)	(1.1)	48.7	74.7	
			1.7	1.7	2.6	Other
Share of post-tax profit of joint ventures	0.6	0.5	—	1.1	1.8	Other
Finance costs	(4.0)	(0.8)	—	(4.8)	(6.3)	Interest, net
					(1.3)	STG&A
Finance income	0.2	—	—	0.2	0.3	Interest, net
Profit before tax	55.9	(9.6)	0.6	46.9	71.8	
Income tax costs - ordinary activities	(19.6)	(11.5)	0.6	(30.5)	(46.7)	Income tax benefit (provision)
Income tax costs - exceptional items	17.4	1.8	—	19.2	29.4	Income tax benefit (provision)
Profit for the period	£53.7	£ (19.3)	£ 1.2	£ 35.6	$ 54.5	
Adjustments to reconcile to Adjusted EBITDA:						
Finance costs of £4.0, net of Finance income of £0.2	£3.8	£ 0.8	£ —	£ 4.6	$ 7.0	Interest expense, net
Income tax costs - ordinary activities of £19.6 net of Income tax costs - exceptional items of £(17.4)	2.2	9.7	(0.6)	11.3	17.3	Income tax expense (benefit)
Depreciation	6.8	1.4	1.0	9.2	14.1	Depreciation and amortization expense
			(1.8)	(1.8)	(2.8)	Foreign exchange losses (gains) on foreign denominated external and

						internal debt
Litigation settlements	(0.7)	—	0.7	—	—	Legal settlements
Restructuring charges	3.0	1.1	(0.3)	3.8	6.2	Restructuring expenses
Corporate development charges	7.9	23.7	(0.4)	31.2	47.4	Corporate development costs
Share of post-tax profit of joint ventures	(0.6)	(0.5)	—	(1.1)	(1.8)	Share of joint venture income
Other	0.5	—	(0.4)	0.1	0.1	Other
Equity based compensation	—	0.2	0.5	0.7	1.1	Long-term compensation issued in connection with acquisitions
Adjusted EBITDA	£76.6	£ 17.1	£ (0.1)	£ 93.6	$ 143.1	

(1) Amounts were calculated utilizing a blended Pound Sterling to U.S. Dollar exchange rate of 1.5156, 1.5334 and 1.5489 for the three month periods ended March 31, 2015, June 30, 2015 and September 30, 2015, respectively, and a blended rate of 1.5168 for the two month period ended November 30, 2015.

DEFINITIONS OF NON-GAAP FINANCIAL MEASURES

For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statements of operations, balance sheets, or statements of cash flows of the company; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented.

To supplement the financial measures prepared in accordance with GAAP, Platform has provided in this prospectus supplement the following non-GAAP financial measures: comparable net (loss) income available to common stockholders, comparable sales, comparable cost of sales, comparable gross profit, Adjusted EBITDA, segment comparable Adjusted EBITDA and segment corporate sales. Management believes that these measures provide useful information to investors by excluding certain items that it believes are not representative of the Company's business and including other items that it believes are useful in evaluating the Company's business; thereby providing a more complete understanding of the Company's operational results and a meaningful comparison of the Company's performance between periods and to its peers. When reconciled to the corresponding GAAP financial measures, these non-GAAP financial measures also help the Company's investors to understand the long-term profitability trends of its businesses. Finally, these non-GAAP financial measures address questions the Company routinely receives from securities analysts, investors and other interested parties in the evaluation of companies in our industry and, in order to assure that all investors have access to the same data, the Company has determined that it is appropriate to make this data available to all. Non-GAAP financial measures are however not prepared in accordance with GAAP, as they exclude certain items as described herein, and may not be indicative of the results that the Company expects to recognize for future periods. In addition, these non-GAAP financial measures may differ from measures that other companies may use. As a result, these non-GAAP financial measures should be considered in addition to, and not a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measure.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the financial tables as part of this prospectus supplement.

Comparable Sales

Comparable sales is defined as sales adjusted to include the sales of Alent, the OMG Businesses and OMG Malaysia as if each of these acquisitions had occurred on January 1, 2015. Management believes this measure provides investors with a more complete understanding of sales trends by providing sales on a more consistent basis.

Adjusted EBITDA and Comparable Adjusted EBITDA

In this prospectus supplement, we present Adjusted EBITDA, which is a key supplemental measure of our performance. We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, as further adjusted for additional items included in earnings that we believe are not representative or indicative of our ongoing business, as described in the footnotes to the reconciliation tables included in this section. Comparable Adjusted EBITDA is defined as Adjusted EBITDA adjusted to reflect the results of Alent, the OMG Businesses and OMG Malaysia and their respective financings as though they each had been completed on January 1, 2015, further adjusted for the effects of purchase accounting on actual results. Adjusted EBITDA and comparable Adjusted EBITDA are key metrics used by management to measure operating performance and trends. In particular, the exclusion of certain expenses in calculating Adjusted EBITDA and comparable Adjusted EBITDA facilitates operating performance comparisons on a period-to-period basis.

The use of Adjusted EBITDA and comparable Adjusted EBITDA is considered relevant to the analysis of Platform's results (net) aside from the material impact of the charges associated with the Prior Acquisitions. We believe Adjusted EBITDA is useful to investors because it is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Our investors regularly request Adjusted EBITDA as a supplemental analytical measure to, and in conjunction with, our GAAP financial data. We understand that these investors use Adjusted EBITDA, among other things, to assess our period-to-period operating performance and to gain insight into the manner in which management analyzes operating performance. In addition, we believe that

Adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry because the calculation of Adjusted EBITDA generally eliminates the effects of financing and income taxes and the accounting effects of capital spending and acquisitions, which items may vary for different companies for reasons unrelated to overall operating performance. Although we believe that Adjusted EBITDA can make an evaluation of our operating performance more consistent, investors should not place undue reliance on Adjusted EBITDA as measures of operating performance. In evaluating Adjusted EBITDA, investors should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments presented herein. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

Adjusted EBITDA has limitations as an analytical tool. Some of these limitations are:

- Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
- Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
- Adjusted EBITDA does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debts;
- Although depreciation is a non-cash charge, the assets being depleted and depreciated will generally have to be replaced in the future;
- Non-cash compensation is and is expected to remain a key element of our overall long-term incentive compensation package;
- Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be representative of our operations; and
- Other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally.

Combined Results, Comparable Adjusted Net (Loss) Income Attributable to Common Stockholders

This prospectus supplement contains unaudited "combined" Predecessor and Successor results for the fiscal year ended December 31, 2013, as well as “comparable” financial information which assumes full period contribution of Alent, and the OMG Businesses, each acquired during the fourth quarter of 2015, and OMG Malaysia acquired during the first quarter of 2016. This combined and comparable information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of our actual results or results that would have been achieved had each of the Alent, OMG and OMG Malaysia Acquisitions been completed as of the dates indicated, or that may be achieved in the future. Historical financial results and information included or incorporated by reference herein relating to these acquired businesses were derived from public filings, when applicable, and/or information provided by management of these businesses prior to their acquisitions by us. In addition, financial information for some of these acquired businesses was historically prepared in accordance with non-GAAP accounting methods, and may or may not be comparable to our financial statements. Consequently, you are cautioned not to place undue reliance on these results and information as they may not be representative of our actual or future results as a consolidated company.

Combined results are the arithmetic addition of the results of the Predecessor (January 1, 2013 to October 31, 2013) and the Successor (April 23, 2013 to December 31, 2013). Comparable adjusted net (loss) income attributable to common stockholders is defined as net (loss) income attributable to common stockholders adjusted to reflect acquisitions and the related financings as though they had occurred on January 1, 2015 without the impact of purchase accounting, as well as other adjustments consistent with our definition of Adjusted EBITDA. Additionally, we eliminate the amortization associated with (i) intangibles assets recognized in purchase accounting for acquisitions and (ii) costs capitalized in connection with obtaining regulatory approval of our products (“registration rights”) as part of ongoing operations and deduct capital expenditures associated with obtaining these registration rights.

RISK FACTORS

In addition to the risk factors incorporated by reference in the prospectus supplement and in the accompanying prospectus, you should carefully consider the risk factors set forth below as well as the other information contained or incorporated by reference in this prospectus supplement, including those risk factors described in Item 1A of Part I of our 2015 Annual Report and in Item 1A of Part II of our 2016 Q2 Form 10-Q, both incorporated by reference in this prospectus supplement and the accompanying prospectus, before investing in our common stock. Any of the following risks could materially and adversely affect our business, financial condition or results of operations. In such a case, you may lose all or part of your investment. This prospectus supplement contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors. See "Forward-Looking Statements" for more information relating to these factors.

Risks Relating to this Offering and Ownership of our Common Stock

We have numerous equity instruments outstanding that could require us to issue additional shares of common stock. Therefore, you may experience significant dilution of your ownership interests and the future issuance of additional shares of our common stock, or the anticipation of such issuances, could have an adverse effect on our stock price.

We have numerous equity instruments outstanding that would require us to issue additional shares of our common stock. Depending on the equity instrument, these additional shares may either be issued for no additional consideration or based on a fixed amount of additional consideration. Specifically, as of September 9, 2016, we had outstanding the following:

- 2,000,000 shares of Series A Preferred Stock which are convertible into shares of our common stock, on a one-for-one basis, at any time at the option of the holder;
- 600,000 shares of Series B Convertible Preferred Stock, issued in connection with the Arysta Acquisition, which are convertible into up to 22,107,590 shares of our common stock at any time at the option of the Arysta seller. Each share of Series B Convertible Preferred Stock will also be automatically redeemed in connection with certain mergers or consolidations, the sale of all or substantially all of the assets of Platform and its subsidiaries, the sale of certain subsidiaries of Platform, or a dissolution, liquidation or termination of Platform. Under the terms of a settlement agreement with the Arysta seller described in the Recent Developments section under "Prospectus Supplement Summary," from October 20, 2016 until the close of business on December 15, 2016, we may (i) settle all of our obligations with respect to the Series B Convertible Preferred Stock in exchange for a cash payment of $1.00 and the issuance of 5,500,000 shares of our common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta seller, and (ii) settle for a payment of $460 million, our obligation to pay the Make Whole Payment (as defined below) to the Arysta seller. To the extent we do not settle all of our obligations by December 15, 2016, we will be required, on April 20, 2017, pursuant to a share purchase agreement among us, the Arysta seller and certain other parties thereto, dated as of October 20, 2014, as amended, to repurchase each share of Series B Convertible Preferred Stock that has not been converted into shares of common stock of Platform, or automatically redeemed as described above. Upon such repurchase, we shall also pay to holders of Series B Convertible Preferred Stock in cash (the "Make Whole Payment") any deficit between (i) the 10-day volume weighted price of our common stock prior to such repurchase and (ii) $27.14 per share. The related potential cash obligation, which varies based on our stock price, corresponds to a maximum amount of $600 million. Based on our common stock price of $8.35 as of September 15, 2016, the maximum potential make whole payment as of September 15, 2016 would total approximately $415 million, assuming no offset from the March 2013 arbitration matter described in our unaudited financial statements for the quarter ended June 30, 2016;
- 7,997,665 exchange rights which require us to issue shares of our common stock in exchange for shares of common stock of our subsidiary, Platform Delaware Holdings, Inc., on a one-for-one basis, at the option of the holder;
- approximately 565,198 options which are exercisable to purchase shares of our common stock, on a one-for-one basis, at any time at the option of the holder, of which 390,198 shares were issued under the 2013 Plan; and
- approximately 2,348,687 RSUs which were granted to employees under our 2013 Plan. Each RSU represents a contingent right to receive one (1) share of our common stock.

We have approximately 12,387,681 shares of our common stock currently available under our 2013 Plan, net of the outstanding RSUs and options noted above (subject to increase in accordance with the terms of such plan) and 373,434 shares issued under the 2013 Plan, and an additional 5,026,150 shares of our common stock currently available under our 2014 ESPP.

In addition, the holders of our Series A Preferred Stock are entitled to receive an annual dividend on their Series A Preferred Stock in the form of shares of our common stock. For 2015, no stock dividend was declared with respect to their Series A Preferred Stock. Since December 31, 2014, the dividend amount is calculated based on the appreciated stock price compared to the highest dividend price (calculated based upon the average of the last ten trading days of the year's volume weighted average share prices) previously used in calculating the Series A Preferred Stock dividends. In 2014, the dividend price was $22.85. Such issuance of common stock as stock dividend in the future could have a dilutive impact on, and reduce the value of, our outstanding common stock.

We have broad discretion in the use of the net proceeds from this offering and our existing cash and may not use them effectively.

Our management will have broad discretion in the application of the net proceeds from this offering as well as our existing cash, and you will be relying on the judgment of our management regarding such application. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Our management might not apply the net proceeds or our existing cash in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from this offering or our existing cash in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.

We may issue preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.

Our Board is authorized to create and issue one or more additional series of preferred stock, and, with respect to each series, to determine the number of shares constituting the series and the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions thereof, which may include dividend rights, conversion or exchange rights, voting rights, redemption rights and terms and liquidation preferences, without stockholder approval. If we create and issue one or more additional series of preferred stock, it could affect your rights or reduce the value of our outstanding common stock. Our Board could, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of our common stock and which could have certain anti-takeover effects.

We cannot assure you that we will declare dividends or have the available cash to make dividend payments.

To the extent we intend to pay dividends on our common stock, we will pay such dividends at such times (if any) and in such amounts (if any) as our Board determines appropriate and in accordance with applicable law. We are also subject to certain restrictions in our financing arrangements which may prohibit or limit our ability to pay dividends. Additionally, for so long as any shares of Series B Convertible Preferred Stock are outstanding, no dividend or distribution may be declared or paid or set aside for payment on all or substantially all the outstanding shares of any other series of preferred stock, other than the Series A Preferred Stock, or common stock without the prior vote or written consent of the holders of at least a majority of the shares of Series B Convertible Preferred Stock then outstanding, voting separately as a single class. We therefore can give no assurance that we will be able to pay dividends going forward or as to the amount of such dividends, if any.

We operate as a holding company and our principal source of operating cash is income received from our subsidiaries.

We are a holding company and do not have any material assets or operations other than ownership of equity interests of our subsidiaries. Our operations are conducted almost entirely through our subsidiaries, and our ability to generate cash to meet our obligations or to pay dividends is highly dependent on the earnings of, and receipt of funds from, our subsidiaries through dividends or intercompany loans. As a result, we are dependent on the income generated by our subsidiaries to meet our expenses and operating cash requirements. The amount of distributions and dividends, if any, which may be paid to us from each of our subsidiaries will depend on many factors, including our financial condition and results of operations, limits on dividends under applicable law, such subsidiary's constitutional documents, documents governing any indebtedness of such subsidiary, and other factors which may be outside our control. If our subsidiaries are unable to generate sufficient cash flow, we may be unable to pay our expenses or make distributions and dividends on our shares of common stock.

Delaware law and provisions in our certificate of incorporation may have anti-takeover implications.
We are governed by Delaware law. The application of Delaware law to us may have the effect of deterring hostile takeover attempts or a change in control. In particular, Section 203 of the Delaware General Corporation Law (the "DGCL") imposes certain restrictions on merger, business combinations and other transactions between us and holders of 15% or more of our common stock. A Delaware corporation may opt out of that provision either with an express provision in its original certificate of incorporation or in an amendment to its certificate of incorporation or by-laws approved by its stockholders. We have not opted out of this provision. In addition, pursuant to our certificate of incorporation, our board has the authority to issue preferred stock without stockholder approval with any rights or preferences. Furthermore, special meetings of stockholders may only be called by our board or the Chief Executive Officer, and there is no cumulative voting in the election of our directors. The provisions of our certificate of incorporation and Section 203 of the DGCL could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us.
Volatility of the trading prices of our common stock and/or senior notes could adversely affect our security holders.
The trading prices of our common stock and our outstanding 6.00% senior notes due 2023 denominated in Euros, 6.50% senior notes due 2022 denominated in U.S. Dollars and 10.375% senior notes due 2021 denominated in U.S. Dollars (collectively, our "Senior Notes") have been highly volatile and could continue to be subject to wide fluctuations in response to various factors, some of which are beyond our control, including, but not limited to:

- quarterly variations in our operating results;
- changes in the market’s expectations about our operating results;
- our operating results failing to meet the expectation of management, securities analysts or investors in a particular period;
- the failure to remediate identified material weaknesses;
- changes in financial estimates and recommendations by securities analysts concerning our Company or our industry in general;
- operating and securities price performance of companies that investors deem comparable to us;
- news reports and publication of research reports relating to our business or trends in our markets;
- changes in laws and regulations affecting our businesses;
- announcements or strategic developments, acquisitions and other material events by us or our competitors;
- sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the perception that such sales could occur;
- adverse market reaction to any additional debt we incur in the future;
- litigation and class action proceedings;
- the failure to identify and complete acquisitions in the future or unexpected difficulties or developments related to the integration of recently completed or future acquisitions;
- actions by institutional stockholders;
- general economic and political conditions such as business cycles, recessions and acts of war or terrorism; and
- the risk factors set forth in this prospectus supplement, the documents incorporated by reference herein and other matters discussed herein and therein.

In addition, the stock market in general, and the market for specialty chemicals companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of companies’ stock, including ours, regardless of actual operating performance. In addition, in the past, following periods of volatility in the overall market and the market price of particular companies’ securities, securities litigation and class action proceedings have often been instituted against such companies. As discussed in our 2016 Q2 Form 10-Q in “Risk Factors—We are subject to a shareholder class action lawsuit which may adversely affect our business, financial condition, results of operations and cash flows,” a class action lawsuit of this type was filed against us in March 2016. There can be no assurance that the market price of our common stock and/or Senior Notes will not fall in the future due to any of the aforementioned factors.
Future sales, or the perception of future sales, of our common stock may depress the price of our common stock.
If we or any of our stockholders sell a large number of shares of our common stock, or if we issue a large number of shares of common stock in connection with future acquisitions, financings or other circumstances, the market price of

our common stock could decline significantly. Moreover, the perception in the public market that we or our stockholders might sell shares of common stock could depress the market price of those shares.
We cannot predict the size of future issuances of our shares of common stock or the effect, if any, that future issuances or sales of our shares will have on the market price of such shares. Sales of substantial amounts of our shares, including sales by significant stockholders, and shares issued in connection with any additional acquisition, or the perception that such sales could occur, may adversely affect prevailing market prices for our shares of common stock. Possible sales also may make it more difficult for us to sell equity or equity-related securities in the future at a time and price we deem necessary or appropriate.

FORWARD-LOOKING STATEMENTS

Certain statements we make in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or therein may constitute “forward-looking statements” within the meaning of the federal securities laws and is intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s Adjusted EBITDA and adjusted diluted earnings per share, expected or estimated revenue, meeting financial goals, segment earnings, net interest expense, income tax provision, cash, taxes paid, cash flow from operations, restructuring costs and other non-cash charges, the size and outlook for the Company’s markets and the demand for its products, consistent profitable growth, free cash flow, future revenues, gross, operating and Adjusted EBITDA margin requirement and expansion, organic net sales growth, performance trends, expansion into key markets, extending our product offering, bank leverage ratio, the success of new product introductions, growth in costs and expenses, the impact of commodities and currencies costs, the Company’s ability to manage its risk in these areas, the Company’s ability to identify, hire and retain executives and other qualified employees, the Company’s assessment over its internal control over financial reporting, and the impact of acquisitions, divestitures, restructuring, and other unusual items, including the Company’s ability to raise new debt and equity and to integrate and obtain the anticipated benefits, results and synergies from its consummated acquisitions. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. These projections and statements are based on management’s estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those projected as a result of certain factors. We believe these factors include, but are not limited to, conditions in the global economy, the variability of our operating results between periods and the resulting difficulty in forecasting future operating results, the anticipated results and synergies from our Prior Acquisitions and future acquisitions, the need for increased spending on capital expenditures to meet customer demand and pursue growth opportunities, our ability to compete successfully within our industry, risks associated with our substantial international operations, fluctuations in foreign currency exchange rates, changes in our customers’ products and processes, the fact that we do not enter into long-term contracts with certain of our customers and the potential loss of those customers, decreases in the average selling prices of products in our industry, increases in the cost, or reductions in the supply, of the specialty and commodity chemicals used in our manufacturing processes, our ability to comply with extensive regulations applicable to agrochemical products, costs related to compliance with health, safety and environmental laws and regulations, including global climate change legislation, our ability to maintain and enhance our technological capabilities and to respond effectively to technological changes in our industry, our substantial level of indebtedness and the effect of restrictions on our operations set forth in the documents that govern such indebtedness, our compliance with certain financial maintenance covenants in our revolving credit facility and the effect on our liquidity of any failure to comply with such covenants, our ability to protect our intellectual property, on which our business is substantially dependent, and our success in avoiding infringing the intellectual property rights of others, acquisitions of businesses and our ability to integrate acquired operations into our operations, the inherently hazardous nature of chemical manufacturing in industries including agricultural, electronics, graphic arts, metal and plastic plating, the costs of complying with government regulations and obtaining regulatory approval of our products, risks related to the evaluation of our intangible asset values and the possibility of write-downs, the loss of the services of key personnel, our relationship with our employees, disruptions in our operations or the operations of our suppliers, distributors, resellers or customers as a result of extraordinary events, our ability to realize a benefit from our productivity initiatives, our ability to maintain an effective system of internal controls over financial reporting, our compliance with anti-corruption laws, and our role as a defendant in litigation that results from our business, including costs related to any damages we may be required to pay as a result of product liability claims brought against our customers.

You should read carefully the factors described or referred to in the "Risk Factors" section of this prospectus supplement and the accompanying prospectus to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. Any forward-looking statements that we make in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or therein speak only as of the date of such statement, and we undertake no obligation to update such statements. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

USE OF PROCEEDS

We estimate that the net proceeds from this offering will be approximately $340 million (or approximately $391 million if the underwriters' option to purchase additional shares is exercised in full), after deducting fees to the underwriters and estimated offering expenses.

We intend to use the net proceeds from this offering for general corporate purposes, including, but not limited to, the alternative settlement of certain obligations relating to our Series B Convertible Preferred Stock.

CAPITALIZATION

The following table summarizes our capitalization and cash and cash equivalents as of June 30, 2016:

- on an actual basis; and
- on an as adjusted basis to give effect to the net proceeds from this offering of common stock, assuming no exercise of the underwriters' option to purchase additional shares.

Other than as described above and in the table below, no other adjustments have been made to reflect normal course operations by us or other developments with our business after June 30, 2016. As a result, the as adjusted information provided below is not indicative of our actual cash and cash equivalents position or consolidated capitalization as of any other date. You should read this information in conjunction with "Use of Proceeds" and "Prospectus Supplement Summary—Summary Financial Data" in this prospectus supplement, and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements, including the accompanying notes, included in our 2016 Q2 Form 10-Q, as well as the historical financial statements of Platform, Arysta and Alent, and the notes to those financial statements incorporated by reference herein.

	As of June 30, 2016 (Unaudited)	
(in millions)	Actual	As Adjusted
Cash and cash equivalents	$341.7	$681.4
Debt:		
Senior secured credit facilities (1)	$3,254.2	$3,254.2
Senior notes (2)	1,952.7	1,952.7
Revolving credit facilities (3)	124.5	124.5
Other short term debt (4)	17.3	17.3
Total debt (5)	5,348.7	5,348.7
Series B Convertible Preferred Stock (6)	645.9	645.9

Total equity	2,567.9	2,907.6